Drugs / GI-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04977453 | Aug 2021 → Jun 2028 expected | cervical cancer, clear cell renal carcinoma, metastatic neoplasm, non-small cell squamous lung carcinoma +1 | GI Innovation, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GI-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04977453 ↗ |
| Modality | Protein / enzyme biologic | “GI-101/GI-101A is a novel bi-specific Fc fusion protein containing the CD80 ectodomain as an N-terminal moiety and an interleukin (IL)-2 variant as a C-terminal moiety...” NCT04977453 ↗ |
| Route | Intravenous | “administered via IV infusion” NCT04977453 ↗ |